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In the absence ofantibody, the alternative pathwayofthe complement system can
function as a first barrierin preventing infection. However, certainmicroorganisms
have developed mechanisms to escape attack and survive in the host's bloodstream
(1). Trypanosoma cruzi, the causative agent ofChagas' disease, is a protozoan parasite
that cycles between invertebrate insect vectors and mammalianhosts. During its de-
velopment in the insect, T . cruzi assumes various forms and the infectivity of the
parasite for the mammalian host is associated with the aquisition of resistance to
lysis by complement (2-5). The epimastigote isthe noninfective multiplicative form
foundin the gut ofthe insect. Epimastigotes transforminto metacyclic trypomastigotes,
which can invade cellsofthemammalian host. While bothepimastigotes andmetacy-
clics activate thecomplement cascade, only epimastigotes are lysed. Metacyclics are
not lysed because they have developed mechanism(s) to prevent the assembly ofC3
convertase, a key amplifying enyzme of the complement system (6-9).
When trypomastigotes enter the host cells, they transform into amastigotes; the
amastigotes then mulitply, transform again into trypomastigotes, and are released
into the bloodstream to continue the cycle. Contrary to the conventional view that
amastigotes are exclusively the intracellular multiplicative stage of the parasite, re-
cent studies demonstrate that amastigotes can be found in circulation during the
acute stages ofthe infection and can enterand develop in cells (10). In vitro infection
of monocytes by amastigotes occurs in the presence of fresh human serum, indi-
cating that they also avoid destruction by complement. These studies, however, did
notdiscriminate betweenlack ofcomplement activation and protectionfrom attack.
Here, we address this question and show that amastigotes are extremely efficient
activators ofthe cascadeandthat they bindterminal components. Functional channels,
however, are not formed and the parasites are not destroyed.
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Materials and Methods
Parasites.
￿
Strain Y of T, cruziwas maintained in monolayers ofLLC-MK2 cellsin DMEM
containing 5% FCS at 370C in a 5°Jo C02 atmosphere. Amastigoteswereobtained as follows.
Trypomastigoteswere collected from a5-d culture ofinfected cellswithin 24hafterchanging
the medium. As determined by light microscopy, most trypomastigotes transformed into
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amastigotes after incubation in liver infusion tryptose (LIT)' medium containing 10% FCS
(LITFCS) for 24 h (11). If necessary, the remaining trypomastigotes were removed by cen-
trifuging the parasites and incubating them for 2 h at 37°C. During this incubation, the con-
taminating trypomastigotes accumulated in the supernatant and the amastigotes remained
in the pellet. Epimastigotes were cultured in LITFCS at 28°C with continuous agitation.
Complement Reagents and Hemolytic Assay.
￿
C8- or C9-depleted human serum (C8dp1, C9dpl)
and C7 were purchased from Cytotech (San Diego, CA). Guinea pig Cl (12), human C2
(13), human C4, human C3, human C5 (14), and human C9 (15) were purified as described.
C6-9 was prepared from guinea pig serum (16). EAC142 and EAC1423 cells were prepared
with sensitized sheep erythrocytes and purified components and used for titration ofC3 and
C5. Normal human serum (NHS), diluted with medium 199 containing 10 mM EDTA or
4 mM MgC12 and 10 mM EGTA, are referred to as EDTA serum and EGTA serum, respec-
tively.
Assayfor the Presence ofLytic Antibodies in Chagasic Sera.
￿
Sera from 43 individuals with chronic
Chagas' disease were obtained from Dr. M. Camargo, University of Sao Paulo, Brazil. "Rb-
labeled amastigotes (2 x 106) were mixed with 10 p,l ofheat-inactivated patients' serum and
25 ul of NHS (1 :1 .25) in a total volume of 100 P1. The mixture was incubated for 30 min
at 37°C, centrifuged, and `Rb in.the supernatants was counted. A pool of patients' sera was
prepared by mixing equal volumes of serum from 43 individuals, and was heat inactivated
at 56°C for 30 min.
Radiolabeling
￿
C3, C7, and C9 were labeled with '251 using Iodogen (Pierce Chemical Co.,
Rockford, IL). The specific activities were between 1 and 10 x 106 cpm/tig protein. The
hemolytic activity of C3 after labeling was 60% of that of the native C3, while the hemolytic
activities of C7 and C9 did not change. 86Rb incorporation into parasites was performed by
incubating 5 x 10' parasites with 50 P,Ci of86Rb in 0.5 ml of LITFCS for 2 h at 37°C . Para-
sites were washed once, resuspended in medium 199, and overlaid onto 1 ml of FCS and
centrifuged. They were washed once more immediately before they were used as target cells
in complement-mediated lysis.
"'I-C3 Binding and Structural Analysis.
￿
Parasites (108/ml) were incubated at 37°C for 30
min in either 10% C8dp1 or 10% heat-inactivated serum containing "5I-C3 in a total volume
of 200 11,1. The reaction was stopped by adding 800 ltl ofcold medium 199 containing 5 mM
EDTA, 1 ug/ml pepstatin, 100 Ag/ml leupeptin, 10 jig/ml soybean trypsin inhibitor, 1 mM
PMSF (Sigma Chemical Co., St. Louis, MO), and 20 hg/ml synthetic elastase inhibitor
Suc(OMe)-Ala-Ala-ProVal-MCA (Penninsula Laboratories, Inc., San Belmont, CA) . The
parasites were washed three times by centrifugation in medium 199 containing 1 mg/ml BSA,
and radioactivity was counted in a gamma counter. To analyze the structure ofC3 associated
with parasites, the pellet was treated with 20 1i1 of 2% SDS in 0.08 Tris buffer (pH 8.8) for
20 min at 37°C. To each parasite lysate, 20 ul of 2 M hydroxylamine in 0.05 M carbonate
buffer (pH 9.0) was added, and the mixture incubated further for 1 h at 37°C. After removal
ofinsoluble materials by centrifugation, 30 141 of 10% glycerol was added. Samples were ana-
lyzed by SDS-PAGE using a 2.5%-15'7o gradient gel under reducing conditions, followed
by radioautography.
12'I-C7 and -C9 Binding and Structural Analysis.
￿
Parasites (108/ml) were incubated with ei-
ther '25I-C7 or 1251-C9 in NHS diluted as described in the text. After incubation, parasites
were centrifuged at 12,000 g for 15 min, washed two times with medium 199 containing 10%
FCS, followed by two further washes with 1 M NaCl. Parasites were then treated with SDS
sample buffer by boiling for 5 min at 100°C and the bound complement molecules were ana-
lyzed in SDS-PAGE using a 2.5%-10% gradient gel. For immunoprecipitation experiments,
the '251-C9 bound to the surface of 2.5 x 10' parasites was extracted with 300 1LI of 1%
3-[(3-chloroamidopropyl) dimethylammonioJ-l-propanesulfonate (CHAPS) (Bio-Rad Labora-
tories, Richmond, CA) in 10 mM Tris buffer containing 0.15 M NaCl, 1001~g/ml leupeptin,
and 1 mM PMSF for 1 h at 4°C. After removal of the insoluble material by centrifugation,
' Abbreviations used in this paper: CHAPS, 3-[(3-chloroamidopropyl) dimethylammonio]-1-propanesul-
fonate; LIT, liver infusion tryptose medium; NHS, normal human serum.IIDA ET AL.
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aliquots were immunoprecipitated with 50 pl (10 Fig/ml) of an mAb that recognizes the neo-
antigen of poly-C9, kindly provided by Dr. R. J. Falk, University of Minnesota (17), with
goat antisera to C9 (Cytotech) (diluted 1 :20) or with control antibodies. After a 4-h incuba-
tion, 201A1 ofprotein A-8epharose (Pharmacia Fine Chemicals, Piscataway, NJ) was added,
and the incubation continued overnight. The Sepharose beadswere washed four times with
PBS containing 1% BSA and 0.5 mM PMSF, and the bound 1251-C9 was counted.
e6Rb Release.
￿
Parasites labeled with 86Rb were incubated with complement reagents.
When kinetic studies were performed, parasites (108/ml) were incubated with equal volumes
of 5% NHS. At indicated times, 100 14 of the reaction mixture was withdrawn into 200 t1
ofcold medium 199, and centrifuged for 3 min at 10,000 g. The supernatants were removed,
the pellets lysed with 100 Ed of 1% NP-40, and e6Rb in supernatants and pellets were counted.
The percent release was calculated using the formula: percent release = [% (T) -
(To)]/[(100 - % (To)]; where % (T) stands for percent 86Rb released from the test sample
incubated for the indicated period of time and % (To) for percent released from the control
with identical reagents without incubation. When dose-dependent release was measured (Fig.
5), and the percent release was shown without subtraction.
Pronase Treatment of Amastigotes.
￿
Amastigotes (108/ml) labeled with 86Rb were incubated
with pronase (Boehringer Mannheim Biochemicals, Indianapolis, IN) at a final concentra-
tion of 1 mg/ml for 10 min at 37'C in medium 199; FCS (50%) was added and the parasites
were pelleted by centrifugation. After further washings, parasites were counted and suspended
to 108/ml and tested for 86Rb release by incubation with either NHS or heat-inactivated
human serum.
Results
Activation of the Complement Cascade by Amastigotes andEpimastigotes.
￿
The parasites
were first tested for their ability to activate the complement cascade. They were in-
cubated with 10% NHS at 37°C for various periods of time, and the remaining
C3 and C5 hemolytic activities in the supernatants were titrated. Both forms ofpara-
sites consumed C3 and C5 with similar efficiencies, and more efficiently than sheep
erythrocytes sensitized with antibody (EA), used as a positive control. Consumption
of C3 by epimastigotes and amastigotes was observed also in EGTA serum, indi-
cating that they are activators of the alternative pathway, whereas under the same
conditions, consumption of C3 by EA, an activator of the classical pathway, was
negligible (Fig. 1).
Consumption ofC3 and C5 lead to the binding of C3 fragments to the parasites .
Parasites were incubated with 10% C8dp1 containing 1251-C3 for 30 min at 37°C.
After repeated washings, 5 .8% and 4.0% of the 1251-C3 remained bound to
amastigotes and epimastigotes, which corresponds to 2.6 x 106 and 1.8 x 106 of
C3 molecules per parasite, respectively. Structural analysis by SDS-PAGE showed
that Cab and iC3b were the two major forms of C3 on both stages of T. cruzi(data
not shown). The effective consumption of C5 and the binding of Cab indicate that
C5-convertase is assembled on the surface of both forms of the parasite.
Binding of Terminal Components and Channel Formation in Membranes ofAmastigotes and
Epimastigotes. We next examined whether the terminal complement components
are activated. Parasites were incubated with various dilutions of NHS containing
1251-C7 for 30 min at 37°C, and washed twice with medium 199 containing 10%
FCS, and twice with 1 M NaCl. 30-40% of the 1251-C7 counts were removed during
the two washes with 1 M NaCl. The remaining 1251-C7 associated with the para-
sites was then determined. Both stages bound similar amounts of C7 (Fig. 2). Next,
the kinetics of 1251-C9 binding was examined. Parasites were incubated in 10% NHS884
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containing "'I-C9 for various periods oftime at 37°C. They were washed as above,
but there was no significant release of labeled C9 during the washings with 1 M
NaCl. As shown in Fig. 3, both stages bound C9, and the plateau was reached after
10 min ofincubation. In contrast to the results with C7, epimastigotes bound four
to six times more C9 than did amastigotes.
Although both stages of the parasite bound C7 and C9, the morphology of
amastigotes was not alteredwhenexamined bylightmicroscopy, whereas epimastigotes
were destroyed. To determine whether small functional channels were formed on
amastigotes, parasites were labeled with 86Rb and incubated with 10% NHS. 60%
ofthe trapped 86Rb was released from epimastigotes within 10 min after the addi-
tion of complement, whereas no significant release from amastigotes was observed
even after 1 h of incubation (Fig. 4).
In other experiments, we measured the release of 86Rb as a function of the
number of '251-C9 bound to the parasites. In one set of tubes, amastigotes and
epimastigotes that had been labeled with 86Rb were incubated with serially diluted
NHS for 30 min at 37°C. In another set of tubes, parasites were incubated with
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FIGURE 1. Consumption of C3
and C5 by amastigotes and epima-
stigotes of T . cruzi. 107 amastigotes
(O), epimastigotes (A), or sensi-
tized sheep erythrocytes (p) were
incubated at 370C in 200 pl of 10%
NHS. Aliquots were withdrawn at
indicated times and centrifuged.
The hemolytic activities ofC3 (a)
and C5 (b) in the supernatant were
titrated and expressed as percent of
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FIGURE 2.
￿
Binding of 1251-C7 to T. cruzi. Amastigotes (O, ")
and epimastigotes (A, A)were incubated in indicated concen-
trations ofeither NHS (O, A) or heat-inactivated serum (0,
A) containing 1251-C7 for 30 min at 37°C. Final concentra-
tion of the parasite in the reaction mixture was 5 x 107/ml.60
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FIGURE 5.
￿
Correlation between C9 binding and 86Rb release. Ama-
otes (O) and epimastigotes (A), at a final concentration of 5 x
/ml were incubated with various dilutions of NHS at final con- ,,
centrations as indicated, containing 1251-C9 for 30 min at 37°C (a).
s6Rb release experiments were performed as in Fig. 3, except that
the incubation time was 30 min (b). Closed symbols represent con-
trols of parasites incubated with heat-inactivated serum.
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FIGURE 3.
￿
Kinetics of 1251-C9 binding to T . cruzi. Amasti~otes (O) and
epimastigotes (A) were incubated with NHS containing 'Al-C9 for the
indicated period of time at 37°C. Final concentrations of parasites and
NHS were 5 x 107/ml and 10%, respectively.
FIGURE 4
￿
Release of 86Ru from parasites Amastigotes . .
(O, ") and epimastigotes (A, A) labeled with 86Rb were
incubated with NHS (O, A) or heat-inactivated serum (0,
A) at 37°C for the indicated periods oftime. Final concen-
trations of parasites and sera were 5 x 107/ml and 10%,
respectively.
NHS diluted identically but containing 1251-C9. At the end of incubation the
amounts of 86Rb released from, and 1251-C9 bound to, the parasites were deter-
mined. The release of 86Rb from epimastigotes was proportional to the bound C9,
whereas 86Rb was not released from amastigotes, even when 1.8 x 105 molecules
of C9 had bound per parasite (Fig. 5).
Characterization ofC9Bound to Amastigotes and Epimastigotes.
￿
Although binding of
C7 and C9 to amastigotes did notlead to the channel formation, thebound C9 had
the characteristic properties of polymerized C9 (poly-C9). By SDS-PAGE analysis
under reducing conditions, it remained at the top of a 2.5-10% gradient gel, with
an apparent Mr. >500,000 (Fig. 6). Furthermore, the bound C9 expressed a unique
epitope of poly-C9. This was determined as follows. Parasites were incubated with886
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FIGURE 6.
￿
SDS-PAGE analysis ofC9 bound to parasites . Amas-
tigotes (lanes 2and 3) and epimastigotes (lanes 4 and 5) were incu-
bated with either C8dp1 (lanes 2and 4) or C9dp1 lanes 3 and 5)
containing 1251-C9, at final concentrations of 10 parasites/ml,
10ofo serum, and 5pg/ml 1251-C9 for 30 min at 37°C . Parasites
were lysedand analyzed by SDS-PAGE using a 2.5-10% gradient
gel under reducing conditions. Lane 1 is a control containing 1251-C9 .
10% NHS containing 1251-C9 for 30 min at 37°C, washed as described, and ex-
tracted with 1% CHAPS. 85% of the bound 1251-C9 counts were solubilized from
amastigotes and epimastigotes . The extracts were then immunoprecipitated with
an mAb to the C9 neoantigen . 42% and28% of the counts were removed from the
amastigote and epimastigote CHAPS extracts, respectively. A control antibody re-
moved 1% of the counts .
To verify whetherthe boundpoly-C9 was inserted into the membrane of the para-
sites, we treated the parasites with trypsin . Others have shown that as the terminal
complement components insert deeper in the membrane, theybecome less suscep-
tible to release by proteolytic enzymes (18) . Amastigotes and epimastigotes were in-
cubated with NHS containing 1251-C9, washed, and then exposed to 100 Fig/ml of
trypsin at37°C for 15 min . 63% ofthe counts were released from amastigotes, while
only 8% were specifically released from epimastigotes (Table I) . Almost all of the
released C9 was of high molecular weight, migrating at the top of the 2.5-10% gra-
dient gel .
Conversion ofAmastigotes into Complement-sensitive Organisms.
￿
In an attempt to over-
come the resistance of amastigotes to complement lysis, we incubated "Rb-labeled
parasites with 10% NHS in the presence of pooled sera from patients with chronic
Chagas' disease. 56% of $6Rb was released during 30 min of incubation at 37°C .
When tested individually, however, only seven of these sera were highly lytic, but
the majority ofthem (24:43) did notinduce significant lysis . All sera contained anti-
bodies to Ssp-4, the major surface glycoprotein of amastigotes, as determined by
immunofluorescent staining and atwo-site immunoradiometric assay (19). Amastigotes
pretreated with proteolytic enzymesalso became susceptible to complement . Pronase-
TABLE I
1251-C9 Releasefrom the Surface of T . cruzi by Trypsin Treatment
T . cruzi Incubated with :
1251-C9 released
170
Amastigotes Trypsin 75
Medium 12
Epimastigotes Trypsin 20
Medium 12IIDA ET AL.
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FIGURE 7.
￿
Loss of resistance to complement attack. 'Rb release
from pronase-pretreated amastigotes by incubation with NHS(A),
or from nontreated amastigotes by incubation with NHS in the
presence ofapool ofChagasic sera (O)wasmeasured kinetically.
As controls, amastigotes incubatedeither with NHS (O), or with
heat-inactivated serum(")are shown. Finalconcentrationof NHSs
ofheat-inactivated serum, andofthepool ofChagasic sera was 10%.
treated amastigotes released 60% of 86Rb by incubation with 10% NHS (Fig. 7).
However, when the pronase-treated amastigoteswere incubated at 37°C in medium
for24 hbefore complement treatment, they againbecame resistantto lysis(not shown).
Discussion
Parasites have developed different strategies to avoid destruction by the comple-
ment system, and in many instances they acquire this ability only at stages ofdevel-
opment that are infective for themammalian host . In thecase of T . cruzi, the nonin-
fective epimastigotes disintegrate when treatedwith complement, whileinfectiveforms,
that is, metacyclics (4-8), blood stage trypomastigotes (3, 8, 9), and amastigotes,
are notlysed when incubatedin fresh human serum. The main findingof this paper
is that the amastigotes activate the alternative complement pathway effectively, but
are not killed because the C5b-9 complexes that bind to the parasite surface fail to
insert into the plasma membrane.
As shown in Fig. 1, a large proportion of C3 and C5 is rapidly activated when
either amastigotes or epimastigotes are incubated in fresh serum. The efficiency of
the consumption of these complement components is even greater than that of an
equivalent number of sheep erythrocytes optimally sensitized with antibodies. Com-
plement activation leads to the deposition of similar amounts of C3 fragments on
the surfaceof both stages ofthe parasite. In fact, because epimastigotes have a much
larger surface area than amastigotes, the density of C3 fragments must be greater
on the latter. Although precise surface areas have not been determined, the spher-
ical amastigotes have an approximate diameter of 3-4 ,,m, while the polymorphic
fusiform epimastigotes have width and length of0.5-3 and 30-50 /.Lm, respectively.
Assembly of C5-convertase is followed by the rapid deposition of a large number
of C7, C9, and presumably C8 molecules on the membrane of epimastigotes and
amastigotes. Contrary to the results of C3 and C7 binding, four to six times more
C9 is bound on epimastigotes (Fig. 3). Thus, the C9/C5b67 ratios are much larger
on the complement-sensitive epimastigotes. This difference could be functionally
significant; for example, killing ofEscherichia coli by complement is only optimalwhen
the C5b-9 complex contains a critical number of C9 molecules (20). Channel size
increases with increasing numbers ofC9 moleculesperC5b67 complexes, and larger
channels are presumably more efficient in inducing lysis (21, 22).
An unexpected finding is that the C9 molecules foundon the resistant amastigotes
have properties of poly-C9, that is, they migrate as high M, complexes after boiling888
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in SDS in the presence of urea, or even after trypsin treatment (23). It could be
argued that the high M, material represents monomer C9 bound to a large para-
site surface molecule. This is, however, unlikely, since monomer C9 is trypsin sensi-
tive and, moreover, a large proportion ofthe high M, C9 can be immunoprecipi-
tated with an mAb directed against the neo-antigen expressed on poly C9.
High Mr C9 is also found on the epimastigotes but it differs from that found on
amastigotes with respect to one important property: the C9 bound to epimastigotes
isnotremovedbytreatment withtrypsin (Table I), while most oftheC9 onamastigotes
is accessible andis removed from the parasite surfacebytreatment withthe enzyme.
The C9 released from amastigotes by trypsin is of high Mr, which is in agreement
with the observation that poly-C9 is mostly resistant to proteolysis (24). The site
oftrypsin cleavage is not known. We favor the idea that C5b-9, containing poly-C9,
binds to a surface molecule ofthe parasite, and that it isthismolecule that is cleaved
by trypsin. Alternatively, the C5b-9 complex may be bound to the membrane in
such a way that trypsin cleaves one or more of its components. In either case, the
C5b-9 complexes are not inserted in the lipid bilayer of amastigote membrane in
the same molecular orientation as they are in the membrane of epimastigotes. In
fact, they may not be inserted into the amastigote lipid bilayer at all. This is consis-
tent with our observation that there is no 86Rb release from amastigotes (implying
a lack of channels) despite binding of C5b-9 to the membrane (Fig. 5).
Activation of terminal complement components in the absence oflysis has been
also reported in the case ofpromastigotes of Leishmania parasites. However, in this
instance, although C9 is efficiently consumed, there is minimal C9 deposition on
the parasite surface (25, 26). This is in contrast to our results with the amastigotes
of T . cruzi in which large amounts of C9 are bound stably to the surface (Fig. 3).
The general features of the interaction between amastigotes and complement
resemble closely those described in studies using the serum-resistant and -sensitive
strains of Neisseria gonorrhoeae. Both strains activate the complement, bind similar
numbers ofC9 molecules to their surfaces, and the C9 appears as a large aggregate
(27). Also, a larger proportion of the C9 bound to the resistant strain is accessible
to cleavage by trypsin, showing that the configurations ofthe terminal complement
complexes are different in the two strains (28). Whether these similarities between
Neisseria and T . cruzi amastigotes reflect the utilization ofanalogous molecular mech-
anisms by these pathogens to protect themselves against complement damage is not
known.
A possible mechanism for accumulation ofnonfunctional C5b-9 complexes is that
hydrophobic domains ofparasite surface molecules serve as nonspecific "traps" for
nascent C5b67 complexes. The efficiency ofthese traps would be greater if the C5-
convertase is assembled atadistance fromthe lipid bilayer. The anomalouslybound
C5b67 might thenbind C8 and C9 inefficiently. This would explainthelow C9/C5b67
ratios found on amastigotes.
Alternatively, ifthe C5b67 complexes reach the membrane ofamastigotes, a sur-
face component may function as a specific inhibitor of C8 and C9 incorporation
andprevent channel formationandenlargement. That is, the putativeinhibitorcould
be functionally analogous to the homologous restriction factor (HRF, or C8bp) of
mammalian cells, which protects them from attack by autologous complement (29,
30). Both the trap hypothesis, and the HRFlike inhibitor hypothesis, postulate the11DA ET AL.
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formation of complexes between parasite surface molecules and terminal comple-
ment components and are therefore subject to experimental verification. The sur-
face molecule involved in this interaction is likely to be protein because amastigotes
become sensitive to complement attack after pronase treatment (Fig. 7).
Others have shown that T . cruzi metacyclic trypomastigotes are poor activators
of complement andthat this can be explained by the production of an inhibitor that
accelerates thedecayoftheC3-convertase (8, 9). While we have notspecifically searched
for this inhibitory activity in extracts ofamastigotes, their resistance to complement
cannot be explained in the same manner since large amounts of C3 fragments are
deposited, and the C5-convertase is assembled. In the mammalian host, the insect-
derived metacyclics transforminto amastigotes. It appears, therefore, that the strategy
used by this parasite to avoid destruction must change in different phases of the life
cycle. This is compatible with the observation that T . cruzi parasites undergo pro-
found morphological remodeling, andexpress novel sets of membrane antigens when
they transform from flagellates into amastigotes (11). However, precise events at the
molecular level need to be determined, before the definitive conclusion that mecha-
nisms of resistance to complement are stage specific is reached.
Finally, regardless ofthe mechanism of resistance of amastigotes to complement,
the finding that large amounts of C3 split products and C5b-9 accumulate on their
surface membrane raises the possibility that some of these complement fragments
enhance the parasite's survival in the mammalian host. In this respect, it is remark-
able that the amastigotes were not destroyed by complement, even in the presence
of antibodies from the majority of patients with chronic Chagas' disease.
Summary
We studied the effect of complement on twolife cycle stages ofthe protozoanpara-
site Trypanosoma cruzi: epimastigotes, found in the insect vector, and amastigotes,
found in the mammalian host. We found that while both stages activate vigorously
the alternative pathway, only epimastigotes are destroyed.
The amounts ofC3 andC5b-7 deposited on the amastigoteswere similar to those
bound to the much larger epimastigotes. Binding of C9 to amastigotes was four to
six times less than binding to epimastigotes, resulting in a lower C9/C5b-7 ratio.
Although a fairly large amount of C9 bound stably to amastigotes, no functional
channels were formed as measured by release of incorporated `Rb. The bound C9
had thecharacteristic properties of poly-C9, that is, it expressed aneo-antigen unique
to poly-C9, and migrated in SDS-PAGE with an apparent Mr >10' . The poly-C9
was removed from the surface of amastigotes by treatment with trypsin, indicating
that it was not inserted in the lipid bilayer.
Modification of amastigote surface by pronase treatment rendered the parasites
susceptible to complement attack. These results suggest that amastigotes have a sur-
face protein that binds to theC5b-9 complex and inhibits membrane insertion, thus
protecting the parasites from complement-mediated lysis.
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